The beneficial effects of empagliflozin-metformin combination on cardiovascular risk factors in type 2 diabetes mellitus patients
Abstract
Type 2 diabetes mellitus (T2DM) is a multifactorial disease closely associated with increased cardiovascular risk, involving insulin resistance (IR), dyslipidemia, oxidative stress, and systemic inflammation. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has shown cardiovascular benefits beyond glycemic control. This study aimed to evaluate the effects of Empagliflozin-Metformin combination on cardiovascular risk factors in T2DM patients. In this cross-sectional study, 124 participants were divided into three groups: healthy control group (n = 50), T2DM patients treated with metformin alone (Met group, n = 37), and T2DM patients treated with Empagliflozin-Metformin combination (Empa-Met group, n = 37). Serum levels of fasting blood glucose (FBG), HbA1c, lipid profile, insulin, hs-CRP, malondialdehyde (MDA), total antioxidant capacity (TAC), and free thiol groups (-SH) were measured. IR was assessed using the homeostatic model assessment (HOMA-IR), and cardiovascular risk was estimated using the atherogenic index of plasma (AIP) and lipid ratios. The Empa-Met group exhibited significantly higher FBG levels and lower levels of total cholesterol (TC), LDL-C, triglycerides (TG), insulin, LDL/HDL, TC/HDL ratios, and HOMA-IR compared to the Met group. The Empa-Met group also showed significantly higher -SH levels and lower MDA levels compared to the Met group. Correlation analyses revealed significant correlations between oxidative stress markers, IR, and…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 124 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.